Moreover, treatment with the p110β-selective antagonist TGX-221 resulted in a lower degree of phosphorylation of the PI3K catalytic subunit after western assessment in both murine and human wild-type and FXS SNSs. Here, PIK3CD is linked to fragile X syndrome.